000305508 001__ 305508
000305508 005__ 20251126144913.0
000305508 0247_ $$2doi$$a10.1007/s00108-025-01999-x
000305508 0247_ $$2pmid$$apmid:41125821
000305508 0247_ $$2ISSN$$a2731-7080
000305508 0247_ $$2ISSN$$a0020-9554
000305508 0247_ $$2ISSN$$a1432-1289
000305508 0247_ $$2ISSN$$a2731-7099
000305508 037__ $$aDKFZ-2025-02192
000305508 041__ $$aGerman
000305508 082__ $$a610
000305508 1001_ $$0P:(DE-HGF)0$$aAlig, Stefan K$$b0
000305508 245__ $$aWhat is established in the treatment of diffuse large B-cell lymphoma? [Was ist gesichert in der Therapie des diffusen großzelligen B-Zell-Lymphoms?]
000305508 260__ $$aBerlin$$bSpringer Medizin$$c2025
000305508 3367_ $$2DRIVER$$aarticle
000305508 3367_ $$2DataCite$$aOutput Types/Journal article
000305508 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1764164921_3813576$$xReview Article
000305508 3367_ $$2BibTeX$$aARTICLE
000305508 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305508 3367_ $$00$$2EndNote$$aJournal Article
000305508 500__ $$a2025 Dec;66(12):1258-1266
000305508 520__ $$aDiffuse large B‑cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with a median age at diagnosis of 71 years, predominantly affecting older adults. Risk factors include immunodeficiency, autoimmune disorders, viral infections, and certain environmental exposures, although most cases lack a clear predisposition. Diagnosis is based on lymph node excision, histopathological and molecular analysis, and positron emission tomography-computed tomography (PET-CT) staging. First-line standard therapy is R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), de-escalated to four cycles for young, low-risk patients (FLYER trial). For patients with International Prognostic Index (IPI) ≥ 2, the POLARIX trial showed superior progression-free survival with polatuzumab vedotin-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) over R‑CHOP. Older patients are generally treated with dose-reduced R‑mini-CHOP or alternatives. In relapsed/refractory disease, chimeric antigen receptor (CAR) T‑cell therapy with axicabtagene ciloleucel or lisocabtagene maraleucel has replaced high-dose chemotherapy with autologous stem cell transplantation for refractory or early relapses, including transplant-ineligible patients. Additional antibody-based therapies-such as polatuzumab-bendamustine-rituximab, tafasitamab-lenalidomide, loncastuximab, and bispecific antibodies (glofitamab, epcoritamab, odronextamab)-expand treatment options, some achieving durable remissions. Glofitamab plus gemcitabine-oxaliplatin is a new standard for first relapse when CAR T‑cell therapy is not feasible or as bridging before CAR T. Future directions include earlier integration of immunotherapies, personalized strategies guided by genetic subgroups, and broader use of liquid biopsy for subtyping, minimal residual disease detection, and treatment guidance.
000305508 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305508 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305508 650_7 $$2Other$$aAntibodies, bispecific
000305508 650_7 $$2Other$$aCAR T‑cell therapy
000305508 650_7 $$2Other$$aCHOP protocol
000305508 650_7 $$2Other$$aLymphoma, non-Hodgkin
000305508 650_7 $$2Other$$aRituximab
000305508 7001_ $$0P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2$$aReinhardt, Annekathrin$$b1
000305508 7001_ $$0P:(DE-HGF)0$$avon Tresckow, Bastian$$b2
000305508 773__ $$0PERI:(DE-600)3124793-3$$a10.1007/s00108-025-01999-x$$n12$$p1258-1266$$tDie Innere Medizin$$v66$$x2731-7080$$y2025
000305508 909CO $$ooai:inrepo02.dkfz.de:305508$$pVDB
000305508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000305508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000305508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000305508 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305508 9141_ $$y2025
000305508 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000305508 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000305508 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINNERE MED : 2022$$d2025-01-07
000305508 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000305508 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000305508 980__ $$ajournal
000305508 980__ $$aVDB
000305508 980__ $$aI:(DE-He78)ED01-20160331
000305508 980__ $$aUNRESTRICTED